Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone

M. Tsimberidou, Apostolia; Catovsky, Daniel; Schlette, Ellen; O’Brien, Susan; G. Wierda, William; M. Kantarjian, Hagop; Garcia‐Manero, Guillermo; Wen, Sijin; Do, Kim‐Anh; Lerner, Susan; J. Keating, Michael

doi:10.1002/cncr.21931

Public

Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone

Published in Cancer • May 12, 2006

Authors:

Apostolia M. Tsimberidou

Daniel Catovsky

Ellen Schlette

Abstract

BACKGROUND: The optimal management of patients with splenic marginal zone lymphoma/marginal zone lymphoma (SMZL) is controversial. The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or chemot...

Subject

Rituximab

Medicine

Splenic marginal zone lymphoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!